Pfizer COVID-19 vaccine appointments are available to our patients. Sign up for Connect today to schedule your vaccination.
Joint Clinical Trials Office
A Randomized Double-Blind Placebo-Controlled Phase II Multi-Center Study of Inflammation Modification of Canakinumab to Prevent Leukemic Progression of Clonal Cytopenias of Unknown Significance (CCUS): IMPACT Study
Study Status:
Open to Enrollment
Primary Investigator:
Date: May 14, 2024
Phase I Multicenter, Open-Label, First-in-Human Study of ORM-5029 in Subjects with HER2-Expressing Advanced Solid Tumors
Study Status:
Open to Enrollment
Primary Investigator:
Date: May 14, 2024
A Phase 3, Open-label, Randomised Study of Datopotamab Deruxtecan Versus Investigator’s Choice of Chemotherapy in Patients who are not Candidates for PD-1/PD-L1 Inhibitor Therapy in First-line Locally Recurrent Inoperable or Metastatic TNBC
Study Status:
Open to Enrollment
Primary Investigator:
Date: May 14, 2024
Technical Development for Fetal and Neonatal MRI
Study Status:
Open to Enrollment
Primary Investigator:
Date: May 7, 2024
Assessment of Placental Perfusion and Oxygenation Using Novel MRI Approaches
Study Status:
Open to Enrollment
Primary Investigator:
Date: May 7, 2024
A Randomized Phase III Trial of Pre-Operative Compared to Post-Operative Stereotactic Radiosurgery in Patients with Resectable Brain Metastases
Study Status:
Open to Enrollment
Primary Investigator:
Date: April 23, 2024
A Phase 1, Open-Label, Multicenter, Dose Escalation and Expansion Study of KB707 in Subjects with Locally Advanced or Metastatic Solid Tumor Malignancies
Study Status:
Open to Enrollment
Primary Investigator:
Date: April 23, 2024
A Multicentre, Phase II, Open-label Study to Evaluate the Efficacy of Acalabrutinib in Combination with Venetoclax and Rituximab in Participants with Treatment Naïve Mantle Cell Lymphoma (TrAVeRse)
Study Status:
Open to Enrollment
Primary Investigator:
Date: April 23, 2024
A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, for Stroke Prevention after an Acute Ischemic Stroke or High-Risk TIA (LIBREXIA-STROKE)
Study Status:
Open to Enrollment
Primary Investigator:
Date: April 17, 2024
Comparison of Anti-coagulation and anti-Platelet Therapies for Intracranial Vascular Atherostenosis (CAPTIVA)
Study Status:
Open to Enrollment
Primary Investigator:
Date: April 17, 2024